Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2802125 | 0.87 | PTGES (0.51) | PTGESCA1CA2LMNAF10 | |
| SCHEMBL2805182 | 0.84 | PTGES (0.56) | PTGESCA1CA2ADRB1 | |
| SCHEMBL13065898 | 0.83 | PTGES (0.48) | PTGESCA1CA2F10 | |
| SCHEMBL2805802 | 0.82 | PTGES (0.56) | PTGESCA1CA2F10ADRB1 | |
| SCHEMBL2803316 | 0.82 | PTGES (0.62) | PTGESCA1CA2LMNAADRB1 | |
| SCHEMBL2806473 | 0.81 | PTGES (0.55) | PTGESCA1CA2ADRB1 | |
| SCHEMBL2802184 | 0.78 | PTGES (0.51) | PTGESCA1CA2LMNAF10 | |
| SCHEMBL2802109 | 0.78 | PTGES (0.42) | PTGESCA1CA2LMNAADRB1 | |
| SCHEMBL2805700 | 0.77 | PTGES (0.69) | PTGESEPHX2ADRB1 | |
| SCHEMBL2802214 | 0.77 | PTGES (0.47) | PTGESCA1CA2LMNAF10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292279-A1 | Bis-(Sulfonylamino) Derivatives in Therapy | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292279-A1 | Bis-(Sulfonylamino) Derivatives in Therapy | PTGER1, SULT2A1, SULT1E1 | PTGES 9/4885CA1 3748/4885CA2 2726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.